Hepatic Function During and Following Three Days of Acetaminophen Dosing in Alcoholics

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

420 participants

Study Classification

INTERVENTIONAL

Study Start Date

2002-01-31

Study Completion Date

2004-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The study objective was to determine whether liver injury develops in alcoholic patients who ingest therapeutic doses of APAP for three consecutive days. Volunteers were recruited from two community detoxification centers to take either acetaminophen (4 g/day) or placebo for 3 consecutive days and remain in the facility an additional 2 days for monitoring. The primary measures were aminotransferase measures taken at baseline and Days 2-5. We hypothesized that there would be no difference in aminotransferase measures between the acetaminophen and placebo study groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Hepatic Function in Alcoholics Following 5 Days of Acetaminophen Dosing

NCT00427206

Alcohol Related Disorders

COMPLETED PHASE4

Effects of Therapeutic Doses of Acetaminophen in Moderate Drinkers

NCT00400621

Moderate Alcohol Consumption (1-3 Drinks Per Day)

COMPLETED PHASE4

Acetaminophen Adduct Formation in Non-Drinkers Taking Therapeutic Doses of Acetaminophen for Ten Consecutive Days

NCT00616018

Drug Induced Liver Injury

COMPLETED PHASE4

Aminotransferase Trends During Prolonged Acetaminophen Dosing

NCT00743093

Drug Toxicity Healthy

COMPLETED PHASE4

Acetaminophen-induced Hepatotoxicity in Chronic Alcohol Abusers

NCT00137059

Hepatotoxicity

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alcohol Related Disorders

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SINGLE_GROUP

Blinding Strategy

DOUBLE

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

acetaminophen

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Any patient, regardless of gender or ethnicity, who was:

1. 18 years or older
2. admitted to one of the two controlled access alcohol detoxification centers with a positive BAL at the time of admittance
3. signed a written informed consent form.

Patients were excluded from the study at baseline if any of the following were present:

1. serum acetaminophen level greater than 20 mcg/ml
2. serum AST or ALT levels greater than 200 IU/L
3. INR greater than 1.5
4. if female, positive for beta-subunit of chorionic gonadotropin
5. clinically intoxicated, psychiatrically impaired or unable to give informed consent
6. known hypersensitivity to acetaminophen
7. history of ingesting more than four grams of APAP per day for any of the four days preceding study enrollment
8. currently enrolled in another trial or had been enrolled in another trial in the preceding three months.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes